Projects, Cores & Programs

The TCCN projects and cores aim to utilize innovative nanotechnologies for new therapeutic strategies, methodologies for reliable monitoring of therapeutic efficacy, early detection approaches from biological fluids and advances in imaging, and cancer-prevention protocols for ovarian and pancreatic cancers. 

The TCCN will apply a diverse array of nano-platforms to achieve these aims. While the primary emphasis in the TCCN is on ovarian and pancreatic cancers, it is likely that the new approaches will have applications for many other malignancies.

  • Projects 1 and 2 directly address ovarian cancer
  • Projects 3 and 4 directly address pancreatic cancer

In each oncology focus area, one project involves multifunctional nanoplatforms for the delivery of bioactive agents to the tumors (Project 1- ovarian and Project 3- pancreatic) and the other targets approaches to the cancer-associated vascular endothelia (Project 2- ovarian and Project 4- pancreatic) for imaging and therapy. All projects integrate fundamental investigations in cancer biology, nanotechnology platform development, and pharmaceutical sciences, albeit to different degrees.

The cores are the Biomathematics, Targeting and Nanoengineering. All projects and cores integrate with each other through the sharing of research results and nanotechnology platforms. This integration allows the TCCN to achieve clinical translation of its research breakthroughs, and aggressively manage the risks that are naturally associated with any highly innovative program at a rapid pace. To fuel translation to the clinic, several TCCN investigators have successfully developed spin-off companies based upon their research. 

Collectively, with a combination of synergistic projects supported by cores that provide services to each project and a track record of successful bench-to-bedside translation, the TCCN is uniquely positioned to bring forth highly effective nanotechnology platforms for prevention, therapy and monitoring of ovarian and pancreatic cancers.